Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.

 
Web www.patentalert.com

< Pyrimidine Compounds as Purine Receptor Antagonist

> N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
~ 00452